NEW YORK (GenomeWeb News) – Dutch firm InteRNA Technologies and German firm Cenix BioScience today said that they will collaborate on screening assays for miRNAs and therapeutic targets for cancer.
 
Cenix will use InteRNA’s lentiviral-based miRNA overexpression library in high-throughput screening assays in combination with high-content, multi-parametric phenotypic analyses to determine the biological role of individual miRNAs and to identify cancer drug targets.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

Nov
05
Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.